AC Immune (NASDAQ:ACIU) Posts Earnings Results, Beats Estimates By $0.02 EPS

AC Immune (NASDAQ:ACIU) posted its quarterly earnings results on Wednesday. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.02, FiscalAI reports. AC Immune had a negative return on equity of 100.17% and a negative net margin of 245.32%. The company had revenue of $3.88 million during the quarter, compared to the consensus estimate of $1.62 million.

AC Immune Trading Down 8.7%

ACIU traded down $0.20 during midday trading on Thursday, reaching $2.09. The company’s stock had a trading volume of 14,453 shares, compared to its average volume of 265,208. AC Immune has a 1 year low of $2.02 and a 1 year high of $3.90. The stock’s 50-day moving average is $2.57 and its 200-day moving average is $2.71. The firm has a market capitalization of $212.71 million, a price-to-earnings ratio of -3.87 and a beta of 1.64.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on ACIU. Zacks Research lowered AC Immune from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 28th. Weiss Ratings upgraded shares of AC Immune from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday. BTIG Research reaffirmed a “buy” rating and set a $8.00 price objective on shares of AC Immune in a research note on Wednesday, September 23rd. Finally, HC Wainwright reaffirmed a “buy” rating on shares of AC Immune in a report on Thursday, September 24th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $7.50.

About AC Immune

AC Immune SA is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, focused on developing treatments and diagnostic products for neurodegenerative diseases. Its research primarily addresses Alzheimer’s disease, Parkinson’s disease and related disorders by targeting proteins believed to contribute to disease progression, including amyloid and tau.

The company’s technology platforms include SupraAntigen, which supports the discovery of antibodies and vaccines, and Morphomer, which is used to identify small-molecule compounds that may prevent or modify the abnormal aggregation of disease-associated proteins.